• Rgs16::GFP Screening for PDA Chemotherapy

  2026-09-09

  Layeghi-Ghalehsoukhteh and colleagues developed a concerted cell-and-in vivo screening strategy using Rgs16::GFP to identify chemotherapy combinations for pancreatic ductal adenocarcinoma. The study shows that trichostatin A, gemcitabine, and JQ1 produced stronger antitumor effects in combination than selected single agents, while also illustrating how reporter-guided prioritization can connect cell assays with rapid validation in genetically engineered models.

• Verapamil HCl: A Transporter-Aware Assay Guide

  2026-09-08

  Verapamil HCl is more than an L-type calcium channel blocker in translational assays: it can also alter intracellular drug exposure. This guide shows how to distinguish calcium-dependent biology from transporter-related effects in myeloma, apoptosis, and arthritis inflammation studies.

• ATRA Reverses Cisplatin-Linked PARP Resistance in EOC

  2026-09-08

  The reference study shows that all-trans retinoic acid can reduce cisplatin-induced resistance to PARP inhibition in epithelial ovarian cancer by suppressing a resistance-associated NAD+ and DNA-repair program. Its sequential cisplatin–ATRA–niraparib strategy provides a mechanistic framework for improving maintenance therapy, while also highlighting the need to validate these findings clinically and across molecular subtypes.

• Exosomal SNORD52 Activates JAK2/STAT6 in HCC

  2026-09-07

  The reference study identifies hepatoma cell-derived exosomal SNORD52 as a mediator of M2 macrophage polarization in hepatocellular carcinoma through the JAK2/STAT6 axis. Its experimental framework connects tumor-cell extracellular RNA transfer with macrophage phenotyping and provides a basis for testing pathway dependence in tumor–immune communication.

• AG-490 (Tyrphostin B42): JAK2/EGFR Guide

  2026-09-07

  AG-490, also called Tyrphostin B42, is a research tyrosine kinase inhibitor used to interrogate JAK2, EGFR, ErbB2, STAT, and MAPK signaling. Its reported activity supports mechanistic cancer research and immunopathological state suppression, but product-level potency values should not be treated as clinical efficacy.

• 3X FLAG Peptide: Assay Design by Motif Logic

  2026-09-05

  The 3X (DYKDDDDK) Peptide is more than a bright epitope label: its multivalent sequence, antibody recognition, and buffer sensitivity can shape assay performance. This guide combines practical workflow design with motif-level insights from protein interaction biology.

• Palomid 529 (P529) for ESCC Research

  2026-09-04

  Palomid 529 (P529) provides a practical dual-mTORC1/mTORC2 perturbation strategy for studying ESCC signaling, cisplatin resistance, angiogenesis, and radiotherapy response. This workflow connects the RCN2–PPP2CA–PI3K-AKT findings to controlled pharmacology without overstating evidence that has not yet been tested in the reference model.

• ROS-Responsive Lipid Nanoparticles for Mutant RAS

  2026-09-04

  Cai and colleagues developed a combinatorial library of thioketal-containing, ROS-degradable lipids to improve tumor-selective mRNA delivery. Their lead formulation, BAmP-TK-12, delivered DUF5-encoding mRNA to deplete mutant RAS and produced stronger antitumor activity than a small-molecule RAS inhibitor in the reported models.

• Hsa_circ_0136666 Drives Gastric Cancer Immune Escape

  2026-09-03

  Miao et al. identify hsa_circ_0136666 as an oncogenic circular RNA that promotes gastric cancer growth and CD8+ T-cell-dependent immune escape through the miR-375/PRKDC axis. The study connects PRKDC-dependent PD-L1 phosphorylation with impaired checkpoint protein degradation and shows that LNP-delivered siRNA can improve anti-PD-L1 treatment responses in tumor models.

• Tigecycline Workflows for Resistant Bacteria

  2026-09-03

  Use Tigecycline to connect broth microdilution phenotyping with plasmid, carbapenemase, and strain-transmission analysis. This practical workflow shows how a glycylcycline antibiotic can strengthen multidrug-resistant pathogen studies while avoiding common interpretation and handling errors.

• Exosomal SNORD52 Activates JAK2/STAT6 in HCC

  2026-09-02

  The reference study identifies hepatoma cell-derived exosomal SNORD52 as an intercellular signal that promotes M2 macrophage polarization through the JAK2/STAT6 pathway. Its combination of exosome analysis, macrophage phenotyping, SNORD52 quantification, and pathway-protein profiling provides a useful framework for studying RNA-mediated remodeling of the hepatocellular carcinoma microenvironment.

• NADH Reductive Stress in Mitochondrial Research

  2026-09-02

  NADH, or reduced nicotinamide adenine dinucleotide, is both an electron donor and a sensitive indicator of cellular redox state. This article translates recent Leigh syndrome findings into practical decisions for mitochondrial assays, disease models, and photocatalytic cancer therapy research.

• BMS 599626: From HER Signaling to Translation

  2026-09-01

  BMS 599626 dihydrochloride offers a mechanistically defined EGFR and ErbB2 inhibitor framework for cancer biology, xenograft studies, and senescence-aware translational research. This article connects receptor-level pharmacology with machine learning-enabled senolytic discovery while maintaining a clear boundary between established evidence and forward-looking hypotheses.

• PYR-41: E1 Inhibitor Workflow Guide

  2026-09-01

  Use PYR-41 to interrogate ubiquitin-dependent protein turnover, inflammatory NF-κB responses, and signaling-state changes with orthogonal biochemical and cellular readouts. This guide connects E1 inhibition to practical ubiquitination assays, B-cell signaling experiments, apoptosis assay design, and sepsis inflammation model validation while emphasizing controls for off-target effects.

• Roscovitine (Seliciclib) in CDK Assays

  2026-08-31

  Roscovitine (Seliciclib, CYC202) gives cancer biology research a practical way to connect CDK inhibition with reversible cell-cycle phenotypes. This workflow combines dose–response design, orthogonal late-prophase readouts, and data-driven compound-selection principles to improve assay interpretability.

8075 records 3/539 page Previous Next 12345 下5页 Last page